US · Healthcare · Biotechnology
EPS came in at -0.11 against a street estimate of -0.17 — a beat of 35.3%.
Analysts rate Iovance Biotherapeutics Inc a buy (8 buy, 2 hold, 0 sell out of 10) with an average price target of $14.30.
CONFIDENT Record Q2 revenue of $99.3M (+66% YoY) and 56% margin. Ampagni demand accelerating with 95 ATCs expanding to 110 by year-end. Lung 202 enrollment nearly complete; guidance update coming Q3. Q2 2026 Canada and Australia approved Ampagni; private-pay ATCs activating in Australia. EU resubmission and UK/Switzerland submissions pending. ~30k addressable melanoma patients globally annually. Analysts probed demand sustainability (organic growth confirmed), Lung 202 timing (post-enrollment, likely Q4), and community ATC scaling (higher ceilings, lower referral friction). Management confident in continued acceleration through 2026 and deferred full-year guidance to Q3 pending demand clarity. 2026-08-06…
Full summary in the app.
| Fund | Stake |
|---|---|
| BlackRock Inc | 8.16% |
| Mhr Fund Management Llc | 6.39% |
| State Street Corp | 5.40% |
| Two Sigma Investments LLC | 4.20% |
| Vanguard Capital Management, LLC | 4.02% |
| Vanguard Portfolio Management, LLC | 3.18% |
| Geode Capital Management, LLC | 2.28% |
| Millennium Management LLC | 1.88% |
| Document | Date |
|---|---|
| Quarterly report · Q3 2026 HEADLINE NUMBERS • Third-quarter 2026 product revenue was $121.469 million, up from $67.455 million in the third quarter of 2025. • Nine-month 2026 | 2026-11-05 |
| Company announcement · Q4 2026 OTHER NOTABLE POINTS • Iovance Biotherapeutics filed an 8-K on November 5, 2026, reporting an updated corporate presentation. • The presentation is | 2026-11-05 |
| Results announced · Q4 2026 HEADLINE NUMBERS • Third-quarter 2026 total product revenue was $121.469 million, up ~80% from $67.455 million in 3Q25 and ~22% from ~$99 million in | 2026-11-05 |
| Company announcement · Q4 2026 HEADLINE NUMBERS • On October 29, 2026, Iovance Biotherapeutics announced updated results from Cohorts 1 and 2 of its Phase 2 IOV-LUN-202 trial. • T | 2026-10-29 |
| Company announcement · Q4 2026 OTHER NOTABLE POINTS • Iovance Biotherapeutics filed an SEC Form 8-K dated October 5, 2026. • The filing reports that the company updated its corpor | 2026-10-05 |
| Company announcement · Q3 2026 HEADLINE NUMBERS • Iovance Biotherapeutics filed a Form 8-K on September 29, 2026. • The filing states that the company updated its full-year 2026 r | 2026-09-29 |
| Quarterly report · Q2 2026 IOVANCE BIOTHERAPEUTICS, INC. - Q2 2026 10-Q SUMMARY HEADLINE NUMBERS • Total Revenue (6M 2026): $170.7 million vs $109.3 million (6M 2025) — increa | 2026-08-06 |
| Company announcement · Q3 2026 IOVANCE BIOTHERAPEUTICS, INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • No financial metrics or headline numbers provided — this Form 8-K is a disclosur | 2026-08-06 |
Readable in the app.
| Announcement | Date |
|---|---|
| Full year 2026 revenue guidance updated Iovance Biotherapeutics issued an 8-K filing on September 29, 2026, announcing an update to its full year 2026 revenue guidance. The actual press release with specific numbers and details is | 2026-09-29 |
| Updated corporate presentation reaffirms full-year 2025 revenue guidance range Iovance Biotherapeutics updated its corporate presentation on January 9, 2026, reaffirming its previously disclosed full-year 2025 revenue guidance of $250-$300 million. This guidance repres | 2026-01-09 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Iovance Biotherapeutics Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.